Why Actinium Pharmaceuticals Inc. [ATNM] Stock Can Charge Above The $11.02 Level

Actinium Pharmaceuticals Inc. [ATNM] has traded in a range of $4.71 to $19.47 in the last 1 year. As of this writing, the stock is at $11.02, up 1.71%. To check whether the stock’s short-term amount has a thrust, its good to check stock’s recent movement. Over the last week, ATNM shares are -3.13% down with the monthly amount drift of -3.99% and seems bad in a long time frame.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


On 7, December 2020, Actinium Announces Positive Interim Results from Iomab-B Pivotal Phase 3 SIERRA Trial at 75% of Total Patient Enrollment at the 62nd American Society of Hematology Annual Meeting. According to news published on Yahoo Finance, Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (“Actinium” or the “Company”) today announced that interim data from its ongoing pivotal Phase 3 trial in patients with relapsed or refractory Acute Myeloid Leukemia (R/R AML) were presented in an oral presentation at the 62nd American Society of Hematology (ASH) annual meeting. Through 75% of patient enrollment, 100% (49/49) of patients receiving a therapeutic dose of Iomab-B in SIERRA have successfully proceeded to Bone Marrow Transplant (BMT) compared to 16% (9/56) of patients in the control arm who received physician’s choice of salvage therapies. The control arm includes a wide range of salvage therapies, including targeted agents, as there is no standard of care in this setting. Of the 84% (47/56) of patients that did not achieve complete remission on the control arm, 64% (30/47) of patients crossed over to receive Iomab-B with 100% (30/30) of those patients successfully proceeding to BMT. In total, 78% (88/113) of patients enrolled on the SIERRA trial were able to receive a BMT despite this being a patient population not typically considered for BMT.

Analyst Birdseye View:

The most recent analyst activity for Actinium Pharmaceuticals Inc. [AMEX:ATNM] stock was on December 06, 2017, when it was Initiated with a Buy rating from B. Riley FBR Inc., which also raised its 12-month price target on the stock to $2.75. Before that, on November 05, 2020, Alliance Global Partners Recapitulated a Buy rating and elevated its amount target to $25. On October 23, 2017, ROTH Capital Resumed a Buy rating and boosted its price target on this stock to $6. On September 14, 2017, Maxim Group Initiated a Buy rating and increased its price target to $3. On August 25, 2016, ROTH Capital Initiated a Buy rating and increased its price target to $5. On February 29, 2016, H.C. Wainwright Initiated a Buy rating and boosted its amount on this stock to $8. On October 15, 2015, FBR Capital Initiated an Outperform rating and boosted its target amount on this stock to $12. On October 01, 2014, MLV & Co Initiated a Buy rating and improved its amount target to $16.

In the past 52 weeks of trading, this stock has oscillated between a low of $4.71 and a peak of $19.47. Right now, the middling Wall Street analyst 12-month amount mark is $32.50. At the most recent market close, shares of Actinium Pharmaceuticals Inc. [AMEX:ATNM] were valued at $11.02.


The Principal structure of this organization shows its whole liability to whole principal at 20.19 and the whole liability to whole assets at 12.24. It shows enduring liability to the whole principal at 9.65 and enduring liability to assets at 0.06 while looking for an extended time period.

Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 10.38 points at 1st support level, the second support level is making up to 9.91. But as of 1st resistance point, this stock is sitting at 11.09 and at 11.33 for 2nd resistance point.

Actinium Pharmaceuticals Inc. [ATNM] reported its earnings at -$0.36 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.44/share signifying the difference of 0.08 and 18.20% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were -$0.41 calling estimates for -$0.4/share with the difference of -0.01 depicting the surprise of -2.50%.

Important Ratio’s To Watch

Meanwhile, turning our focus to liquidity, the Current Ratio for Actinium Pharmaceuticals Inc. [AMEX:ATNM] is 10.50. Likewise, the Quick ratio is also the same, showing Cash ratio at 1.74. Now if looking for a valuation of this stock’s amount to book ratio is 6.35.